A Case of the Primary Splenic Angiosarcoma Effectively Treated with Recombinant Interleukin-2

Primary splenic angiosarcoma is a rare neoplasm with a dismal prognosis. We report a case of primary splenic angiosarcoma effectively treated with recombinant interleukin-2 (rIL-2) after splenectomy. A 52-year-old woman with a huge splenic tumor underwent splenectomy in September 2002. The resected...

Full description

Saved in:
Bibliographic Details
Published inNippon Shokaki Geka Gakkai zasshi Vol. 38; no. 2; pp. 202 - 207
Main Authors Doi, Koji, Yoshida, Makoto, Nakamura, Tomoaki, Matsumura, Mitsuyoshi, Uchinami, Masaru, Tanaka, Kuniyoshi, Imamura, Yoshiaki
Format Journal Article
LanguageJapanese
Published The Japanese Society of Gastroenterological Surgery 2005
Subjects
recombinant interleukin-2
splenic angiosarcoma
Online AccessGet full text

Cover

More Information
Summary:Primary splenic angiosarcoma is a rare neoplasm with a dismal prognosis. We report a case of primary splenic angiosarcoma effectively treated with recombinant interleukin-2 (rIL-2) after splenectomy. A 52-year-old woman with a huge splenic tumor underwent splenectomy in September 2002. The resected tumor was diagnosed pathologically as angiosarcoma. For simultaneous multiple liver metastases, we initiated continuous hepatic arterial injection with rIL-2. After 1 month of treatment, liver metastases had decreased markedly in size. In March 2003, lymph node metastases were detected developing in the hepatoduodenal ligament. Continuous intravenous injection of rIL-2 gradually decreased lesion size. In May 2003, MRI showed a brain tumor. The tumor was resected, but the specimen had no pathological finding of angiosarcoma. After neurosurgical treatment, she had to discontinue rIL-2 therapy due to adverse side effect, dying 4 months later in September 2003.
ISSN:0386-9768
1348-9372
DOI:10.5833/jjgs.38.202